STOCK TITAN

Ironwood Pharmaceuticals Inc - IRWD STOCK NEWS

Welcome to our dedicated news page for Ironwood Pharmaceuticals (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ironwood Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ironwood Pharmaceuticals's position in the market.

Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) reported 8% year-over-year growth in LINZESS® (Iinaclotide) EUTRx prescription demand, with U.S. net sales of $279 million, a 7% increase. Positive final data from STARS Nutrition for apraglutide in short bowel syndrome and colon-in-continuity was reported. Phase II study of CNP-104 in primary biliary cholangitis topline data expected in Q3 2024. Maintains Full Year 2023 Guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
earnings
-
Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. will host its Q3 2023 investor update conference call on November 9, 2023. The call will be available for replay via telephone and the webcast will be archived on Ironwood's website for 14 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
conferences earnings
-
Rhea-AI Summary
Ironwood Pharmaceuticals presented new data at the ACG 2023 Annual Scientific Meeting and Postgraduate Course, highlighting the impact of linaclotide on symptoms of IBS-C and CIC and the burden of these disorders on patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.49%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.81%
Tags
clinical trial
-
Rhea-AI Summary
Ironwood Pharmaceuticals presents findings showing linaclotide reduces use of rescue medications in children with functional constipation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.16%
Tags
earnings
Rhea-AI Summary
Ironwood Pharmaceuticals will host its second quarter 2023 investor update conference call and webcast on August 8, 2023. The call will be available for replay via telephone and the archived webcast will be available on Ironwood's website for 14 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
conferences earnings
-
Rhea-AI Summary
Ironwood Pharmaceuticals and VectivBio Holding AG have successfully completed the tender offer for the outstanding ordinary shares of VectivBio. The tender offer was priced at $17.00 per share in cash, and approximately 97.60 percent of the outstanding shares were tendered. Ironwood intends to delist VectivBio's shares from Nasdaq and proceed with a squeeze-out merger under Swiss law.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
none
-
Rhea-AI Summary
Ironwood Pharmaceuticals and VectivBio Holding AG have successfully completed the tender offer for the outstanding ordinary shares of VectivBio. The tender offer was priced at $17.00 per share in cash, and approximately 97.60 percent of the outstanding shares were tendered. Ironwood intends to delist VectivBio's shares from Nasdaq and proceed with a squeeze-out merger under Swiss law.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
Rhea-AI Summary
Ironwood Pharmaceuticals and VectivBio announce expiration of waiting period for acquisition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
acquisition
Ironwood Pharmaceuticals Inc

Nasdaq:IRWD

IRWD Rankings

IRWD Stock Data

1.35B
137.03M
2.08%
108.88%
9.91%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Boston

About IRWD

ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b